MegaMD
Daily close in US$ at the latest USD/KRW close. Source: KRX via FinanceDataReader.
MegaMD provides test-preparation and professional-licensing education to university students and working adults in South Korea, listed on KOSDAQ, the country's tech and small-cap exchange.
Its courses cover entry into law school, bar and patent-attorney examinations, and medical-school admissions tests, as well as licensing programmes for real-estate agents, social workers, childcare teachers, and Korean-language instructors. Instruction is delivered through both online and offline channels, with companion textbooks supplied alongside courses. The professional-examination segment accounts for the larger share of revenue, with the licensing segment making up the remainder.
Summary is AI-generated and may contain errors · figures from DART filings
MegaMD in five facts
What does MegaMD do?
MegaMD provides test-preparation and professional-licensing education to university students and working adults in South Korea, listed on KOSDAQ, the country's tech and small-cap exchange.
Where is MegaMD listed and in which sector?
MegaMD (Korean name: 메가엠디) trades under KRX code 133750 on KOSDAQ, the Korea Exchange's board for smaller and growth companies. It is classified in the Consumer Discretionary sector, Consumer Services.
How large is MegaMD?
Its market capitalisation was US$23.4M on 2026-10-21, which puts it in this site's small-cap group. US$ amounts are converted from won at 1 USD ≈ ₩1,325 (2026-10-21).
What were MegaMD's latest annual revenue and operating profit?
For fiscal year 2025, MegaMD reported revenue of US$26.1M, operating profit of US$1.4M and net income of US$2.1M, per its annual report on DART (data retrieved from DART on 2026-09-17). Revenue was down 5.2% on the previous year.
Where does this data come from?
Financial statements and filings come from DART, Korea's official corporate-filing system. Share prices, market capitalisation and trading status come from KRX. Company summaries are AI-generated from the filings and may contain errors; financial figures are mapped directly from DART.
Data sources and last updated
- Filings and financial statements
- DART (dart.fss.or.kr), Korea's official corporate-filing system
- Prices, market cap, trading status
- KRX (Korea Exchange), via FinanceDataReader
- Latest annual financials
- Fiscal year 2025, data retrieved from DART on 2026-09-17
- Share price and market cap
- Close of 2026-10-21
- Currency
- US$, converted from won at 1 USD ≈ ₩1,325 (2026-10-21 close)
- Company data updated
- 2026-10-21
- Company summary
- AI-generated from filings; may contain errors. Information only, not investment advice.
- Cash/in-kind dividend decision
MegaMD declared a cash dividend of US$0.04 per share, equal to about 3.3% of the recent share price.
Dividend · Mar 12 - Change of 30% or more in revenue or profit/loss structure (15% for large companies)
MegaMD reported separate results for FY2025: revenue of US$23.4M (−5.2% year on year), operating profit of US$1.23M (−18.9% year on year) and net income of US$1.89M (−26.3% year on year).
Earnings · Mar 12